Ocular Therapeutix Says FDA Talks Progressing as It Eyes AXPAXLI NDA for Wet AMD on SOL-1 Data

Ocular Therapeutix (NASDAQ: OCUL) Executive Chairman, President, and CEO Dr. Pravin Dugel said the company is engaged in formal discussions with the U.S. Food and Drug Administration as it works toward a New Drug Application submission for AXPAXLI in wet age-related macular degeneration (wet AMD), with the company aiming to support approval based on its SOL-1